bepridil has been researched along with candesartan in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, T; Ito, H; Kawamura, M; Kobayashi, Y; Miyoshi, F; Onuki, T; Tanno, K; Watanabe, N | 1 |
| Kawamura, M; Kobayashi, Y; Munetsugu, Y; Tanno, K | 1 |
2 trial(s) available for bepridil and candesartan
| Article | Year |
|---|---|
Candesartan decreases type III procollagen-N-peptide levels and inflammatory marker levels and maintains sinus rhythm in patients with atrial fibrillation.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biomarkers; Biphenyl Compounds; C-Reactive Protein; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Heart Rate; Humans; Interleukin-6; Kaplan-Meier Estimate; Male; Natriuretic Peptide, Brain; Peptide Fragments; Procollagen; Prospective Studies; Tetrazoles | 2010 |
Carvedilol is effective and safe in combination with bepridil for persistent atrial fibrillation and decreases the QT prolongation induced by bepridil therapy.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzimidazoles; Bepridil; Biphenyl Compounds; Carbazoles; Carvedilol; Disease-Free Survival; Drug Therapy, Combination; Electrocardiography; Female; Heart Rate; Humans; Japan; Kaplan-Meier Estimate; Long QT Syndrome; Male; Middle Aged; Propanolamines; Proportional Hazards Models; Prospective Studies; Secondary Prevention; Tetrazoles; Time Factors; Treatment Outcome | 2013 |